Nov 27, 2023 08:32AM
Nov 27, 2023 08:30AM
Nov 22, 2023 05:00PM
Nov 9, 2023 04:05PM
Nov 3, 2023 05:00PM
Oct 30, 2023 08:00PM
Oct 23, 2023 07:00AM Aeglea Biotherapeutics (AGLE) tech validated on Roche's deal to acqurie rival TL1A program for $7.1B - Stifel
Oct 2, 2023 06:02PM
Sep 14, 2023 05:03PM
Sep 7, 2023 08:43AM
Sep 7, 2023 08:40AM
Sep 5, 2023 07:00AM
Aug 11, 2023 07:00AM
Jul 27, 2023 07:01AM Aeglea BioTherapeutics (AGLE) Sells Pegzilarginase to Immedica Pharma for Up to $115M
Jul 27, 2023 07:00AM
Jul 25, 2023 05:20AM
Jun 23, 2023 04:30PM
Jun 22, 2023 08:22AM
Jun 22, 2023 08:17AM
Apr 12, 2023 07:01AM
Apr 12, 2023 07:00AM Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternativ
Nov 30, 2022 04:44PM
Jul 15, 2021 08:30AM
Dec 17, 2020 04:09PM
Dec 17, 2020 04:05PM
Mar 7, 2019 04:05PM
Mar 7, 2019 04:05PM
Nov 8, 2018 08:00AM Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Nov 8, 2018 08:00AM
Oct 22, 2018 08:06AM
Oct 22, 2018 08:00AM
Oct 22, 2018 08:00AM
Aug 9, 2018 08:00AM
Aug 9, 2018 08:00AM
Jul 30, 2018 04:00PM Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule
Jul 30, 2018 04:00PM
Jul 19, 2018 04:01PM
Jul 19, 2018 04:00PM
Jul 19, 2018 04:00PM
Apr 24, 2018 09:06AM
Apr 5, 2018 08:13AM
Apr 5, 2018 08:00AM Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting
Apr 5, 2018 08:00AM
Apr 2, 2018 08:05AM
Apr 2, 2018 08:00AM
Apr 2, 2018 08:00AM
Mar 8, 2018 08:00AM
Mar 8, 2018 08:00AM
Jul 20, 2017 04:03PM Aeglea BioTherapeutics (AGLE) CEO Resigns
Jul 20, 2017 04:01PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All